Skip to content
Royalty Pharma plc (RPRX) Stock Price, Key Stats & Insider Trading
Home / Companies / RPRX RPR
Royalty Pharma plc (RPRX) XNAS PHARMACEUTICAL PREPARATIONS Net insider selling (90d)
Latest RPRX Insider Trades
About Royalty Pharma plc (RPRX) Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Headquarters NEW YORK, NY
Employees 100
Listed 2020
Exchange XNAS https://www.royaltypharma.com SEC filings for RPRX on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 11 409,199 $23.16M Grant or award 13 132,521 Bona-fide gift 4 68,300
RPRX Insider Transactions (Form 4) 41 65 Form 4 filings on record, the earliest from May 13, 2025, newest first. Filing history page 1 of 3.
Date Insider Transaction Security Shares Price Value Aug 18, 2026 CH Christopher Hite - Officer Open-market sale Class A Ordinary Shares 100,000
Recent RPRX Form 8-K Filings 5
Recent RPRX Form 144 Notices of Proposed Sale 3 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 18, 2026 SCH Investment Partners LLC Officer 100,000 $6.01M View on EDGAR Aug 13, 2026 Terrance Coyne Officer
RPRX Insider Trading - FAQ
What is the latest insider trade for RPRX? Royalty Pharma plc (RPRX) had 19 insider filings in the last 90 days, with the most recent on 2026-08-19. The full record for RPRX runs to 65 Form 4 filings, the earliest from 2025-05-13. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying RPRX stock? No insider purchases of RPRX were filed in the last 90 days.
How many insiders are selling RPRX stock? 11 insider sales of RPRX were filed in the last 90 days, totaling $23.16M.
Where can I see RPRX SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks RPRX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow RPRX insider buys? Create a free InsiderAlpha account and press Watch on this page to add RPRX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track RPRX insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free Aug 13, 2026
Market cap $27.10B
P/E ratio 32.30
Dividend yield -
Average volume 3.36M
52 week high $62.46
52 week low $34.08
Today's high $62.01
Today's low $60.66
Open $61.92
Volume 1.70M
Previous close $61.92
Shares outstanding 445.28M Market cap
$27.10B
100 employees
RPRX Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 11 sales totaling $23.16M.
Most-Active RPRX Insiders - Last 90 Days 10 Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Aug 13, 2026 TC Terrance P. Coyne - Officer Open-market sale Class A Ordinary Shares 9,230 $58.59 $541K
Aug 13, 2026 TC Terrance P. Coyne - Officer Open-market sale Class A Ordinary Shares 1,772 $59.14 $105K
Aug 5, 2026 PL Pablo G. Legorreta - Officer Grant or award Class A Ordinary Shares 65,216 $0.00 -
Aug 7, 2026 PL Pablo G. Legorreta - Officer Gift LP interests in RPI US Partners 2019, LP 30,000 $0.00 -
Aug 5, 2026 TC Terrance P. Coyne - Officer Grant or award Class A Ordinary Shares 11,002 $0.00 -
Aug 5, 2026 CH Christopher Hite - Officer Grant or award Class A Ordinary Shares 11,002 $0.00 -
Aug 5, 2026 MU Marshall Urist - Officer Grant or award Class A Ordinary Shares 8,252 $0.00 -
Aug 7, 2026 MU Marshall Urist - Officer Gift LP interests in RPI US Partners 2019, LP 3,000 $0.00 -
Jul 1, 2026 MU Marshall Urist - Officer Open-market sale Class A Ordinary Shares 9,099 $55.88 $508K
Jun 30, 2026 CH Christopher Hite - Officer Open-market sale Class A Ordinary Shares 97,446 $56.50 $5.51M
Jun 30, 2026 CH Christopher Hite - Officer Open-market sale Class A Ordinary Shares 2,554 $57.10 $146K
Jun 30, 2026 CH Christopher Hite - Officer Open-market sale Class A Ordinary Shares 29,400 $56.44 $1.66M
Jun 30, 2026 CH Christopher Hite - Officer Open-market sale Class A Ordinary Shares 600 $57.09 $34K
Jun 30, 2026 BB Bonnie L. Bassler - Director Grant or award Class A Ordinary Shares 689 $54.40 $37K
Jun 24, 2026 MU Marshall Urist - Officer Open-market sale Class A Ordinary Shares 9,098 $55.18 $502K
Jun 23, 2026 CH Christopher Hite - Officer Open-market sale Class A Ordinary Shares 32,408 $54.11 $1.75M
Jun 23, 2026 CH Christopher Hite - Officer Open-market sale Class A Ordinary Shares 117,592 $54.47 $6.41M
Jun 5, 2026 GN Gregory Norden - Director Grant or award Class A Ordinary Shares 4,545 $0.00 -
Jun 5, 2026 TL Ted W. Love - Director Grant or award Class A Ordinary Shares 4,545 $0.00 -
Jun 5, 2026 DH David C. Hodgson - Director Grant or award Class A Ordinary Shares 4,545 $0.00 -
Jun 5, 2026 CH Carole Ho - Director Grant or award Class A Ordinary Shares 4,545 $0.00 -
Jun 5, 2026 VC Vlad Coric - Director Grant or award Class A Ordinary Shares 4,545 $0.00 -
Jun 5, 2026 BB Bonnie L. Bassler - Director Grant or award Class A Ordinary Shares 4,545 $0.00 -
May 26, 2026 TC Terrance P. Coyne - Officer Open-market sale Class A Ordinary Shares 64,399 $53.98 $3.48M
May 20, 2026 MU Marshall Urist - Officer Open-market sale Class A Ordinary Shares 13,684 $52.75 $722K
May 14, 2026 MU Marshall Urist - Officer Open-market sale Class A Ordinary Shares 13,684 $53.06 $726K
May 14, 2026 GN Gregory Norden - Director Open-market sale Class A Ordinary Shares 3,045 $53.00 $161K
May 6, 2026 PL Pablo G. Legorreta - Officer Grant or award Class A Ordinary Shares 143,821 $0.00 -
May 6, 2026 TC Terrance P. Coyne - Officer Grant or award Class A Ordinary Shares 24,263 $0.00 -
May 6, 2026 CH Christopher Hite - Officer Grant or award Class A Ordinary Shares 24,263 $0.00 -
May 6, 2026 MU Marshall Urist - Officer Grant or award Class A Ordinary Shares 18,197 $0.00 -
Apr 28, 2026 TC Terrance P. Coyne - Officer Open-market sale Class A Ordinary Shares 32,916 $49.78 $1.64M
Apr 28, 2026 TC Terrance P. Coyne - Officer Open-market sale Class A Ordinary Shares 1,875 $49.78 $93K
Apr 1, 2026 TC Terrance P. Coyne - Officer Open-market sale Class A Ordinary Shares 1,875 $48.33 $91K
Apr 1, 2026 TC Terrance P. Coyne - Officer Open-market sale Class A Ordinary Shares 32,916 $48.33 $1.59M
Mar 31, 2026 BB Bonnie L. Bassler - Director Grant or award Class A Ordinary Shares 815 $45.98 $37K
Aug 12, 2026 Errol B. De Souza Former Affiliate 206,352 $11.93M View on EDGAR
$IONS
IONIS PHARMACEUTICALS INC
